Evaluation of the effect of Oshaq Gum on pains radiating to lower limbs

Comparison of the Effectiveness of Oshaq Capsule, Iranian Traditional Medicine Product, with Placebo on Pains Radiating to lower Limbs: A double Blind Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200418047124N1

Enrollment

Registered

2020-05-07

Start date

2020-05-21

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pains radiating to lower limbs. Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention 1: Intervention group: Patients in this group are treated with 500 mg capsules containing 300 mg of Oshaq powder and 200 mg of Anison powder, Standardized by the Department of Iranian Tra

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Having Pains Radiating to lower limbs Patient satisfaction Age 20 to 70 years Pain intensity score is eight or less according to VAS Criteria

Exclusion criteria

Exclusion criteria: Having Cauda equina Syndrom symptoms Surgical history due to back pain Having pains with infectious origin Having Rheumatic pains Pains with glandular and metabolic origin Pain due to tumors Pain due to blood diseases Pain due to Psychological disorders Having surgical indications Having back pain with the participation of the uterus Pain due to inflammation of the nerve root Spinal canal stenosis Spondylolysis Spondylolisthesis Vertebral fracture Ankylosing Spondilytis disease Multiple myeloma Pain due to vascular insufficiency Having osteoporosis with stress fracture Extradural tumors Having peripheral neuropathy Herpes zoster virus infection The severity and abnormal patter of pain Coagulation disorders and Platelet disorders History of upper gastrointestinal bleeding with NSAID Having Renal disease Having Congestive heart failure Cirrhosis pathology

Design outcomes

Primary

Measure	Time frame
Pain Intensity Score. Timepoint: At the beginning of the study and at 1, 2, 3, 4, 5, 6 weeks of study. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
Disability Level. Timepoint: At the beginning of the study and at 3 and 6 weeks of the study. Method of measurement: Roland Morris Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRaefeh Mardi

Tehran University of Medical Sciences

spm@tums.ac.ir+98 21 8897 6527

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026